Market cap

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)) market cap declines to $ 6.0 billion, but insiders who sold $ 4.9 million shares were able to cover their losses

In the past year, insiders have sold for $ 4.9 million Ultragenyx Pharmaceuticals Inc. (NASDAQ: RARE) at an average price of $ 132 per share allowing them to get the most out of their money. The company’s market valuation fell by US $ 496 million after the stock price fell 7.7% over the past week, but insiders were spared painful losses.

While we never suggest that investors should base their decisions solely on what the directors of a company have done, we consider it foolish to ignore insider trading altogether.

Check out our latest review for Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Insider Transactions in the Past Year

In the past twelve months, the biggest sale by an insider was when Director of Quality Operations and Executive Vice President of Translational Sciences John Pinion sold US $ 856,000 worth of shares for $ 138 US per share. We usually don’t like to see insider sales, but the lower the selling price, the more it concerns us. The positive side is that this drop took place above the last price (US $ 87.80). So it might not shed much light on insider confidence at current levels.

Ultragenyx Pharmaceutical insiders have not bought any shares in the past year. Below you can see a visual representation of insider trading (by businesses and individuals) over the past 12 months. If you click on the chart you can see all of the individual trades including the stock price, individual and date!

NasdaqGS: RARE Insider Trading Volume October 3, 2021

If you like to buy stocks that insiders buy rather than sell, then you might love this free list of companies. (Hint: insiders bought them).

Ultragenyx pharmaceutical insiders sell their shares

Over the past three months we’ve seen quite a bit of insider selling at Ultragenyx Pharmaceutical. Executive Vice President and Chief Commercial Officer Erik Harris only sold US $ 34,000 of shares during this period. Neither the lack of buying nor the presence of selling is encouraging. But the sale just isn’t big enough to be of much use as a signal.

Insider Property of Ultragenyx Pharmaceutical

Looking at the total insider stakes in a company can help you determine if they are aligned with common shareholders. I think it’s a good sign if the insiders own a significant number of shares in the company. It’s great to see Ultragenyx Pharmaceutical insiders own 4.8% of the company, worth around $ 286 million. This type of large insider ownership generally increases the chances that the business will be run in the best interests of all shareholders.

So what do Ultragenyx’s pharmaceutical insider trading indicate?

While there have been no insider buys in the past three months, there have been sales. However, sales are not important enough to be of concern to us at all. Encouragingly, insiders own a lot of stocks, but we would like to see more insider buying as the last year of Ultragenyx Pharmaceutical’s insider trading does not give us confidence. So these insider trading can help us build a stock thesis, but it’s also worth knowing the risks this business faces. For example – Ultragenyx Pharmaceutical has 2 warning signs we think you should be aware.

If you would rather consult with another company – one with potentially superior finances – then don’t miss this free list of interesting companies, which have a HIGH return on equity and low leverage.

For the purposes of this article, insiders are the persons who report their transactions to the relevant regulatory body. We currently account for open market transactions and private assignments, but not derivative transactions.

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative documents. Simply Wall St has no position in any of the stocks mentioned.

Do you have any feedback on this item? Are you worried about the content? Get in touch with us directly. You can also send an email to the editorial team (at)

If you decide to trade Ultragenyx Pharmaceutical use the cheapest platform * which is ranked # 1 overall by Barron’s, Interactive brokers. Trade stocks, options, futures, currencies, bonds and funds in 135 markets, all from one integrated account.Promoted

Leave a Reply

Your email address will not be published.